Exchange: NASDAQ·Updated 07:00 AM EDT
ACAD logo

ACAD Acadia Pharmaceuticals Inc

$27.48
$0.72
(2.69%)
Pre-Market
Prev Close $26.76
EarningsNov 4
Mkt Cap$4.61B
Vol64.00

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
29

Bearish Sentiment

How do you feel about ACAD?

Advertisement|Remove ads.